Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Non-interventional Retro- and Prospective Safety and Efficacy Study of Prolgolimab (Forteca - Anti-PD1) in Patients With Advanced Melanoma (FOrteca Real Practice Assessment)

NCT05120024 is registered in ClinicalTrials.gov with MelanomaPRO, Russia as lead sponsor.

NCT NCT05120024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05120024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Non-interventional Retro- and Prospective Safety and Efficacy Study of Prolgolimab (Forteca - Anti-PD1) in Patients With Advanced Melanoma (FOrteca Real Practice Assessment)
Lead sponsor
MelanomaPRO, Russia
Phase
Observational
Overall status
Unknown status
Start date
October 14, 2020
Completion date
December 31, 2023
Enrollment
350 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma